Literature DB >> 7928083

Susceptibility of glycans to beta-elimination in Fmoc-based O-glycopeptide synthesis.

M Meldal1, T Bielfeldt, S Peters, K J Jensen, H Paulsen, K Bock.   

Abstract

In order to investigate the possible extent of beta-elimination occurring in Fmoc-based continuous-flow solid-phase glycopeptide synthesis, the influence of the pKb of the base used for N alpha-deprotection has been studied. A glycosylated pentapeptide was synthesized using 50% morpholine, 10% piperidine or 2% DBU, respectively, in DMF for deprotection. The dehydropentapeptide N alpha-Ac-Thr-Thr-delta Aba-Val-Thr-NH2, which would be formed in the case of beta-elimination, was prepared independently and used as a control in HPLC analysis; however, this product was not formed under any of the deprotection conditions applied. Furthermore, a 23 amino acid long glycopeptide from human intestinal mucin was prepared using 2% DBU as a base for Fmoc cleavage, and similarly no beta-elimination was observed. The glycopeptide products were subjected to a prolonged treatment with sodium hydroxide in methanol/water without significant formation of byproducts, and the pure glycopeptides were isolated and characterized by 1H-NMR spectroscopy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7928083     DOI: 10.1111/j.1399-3011.1994.tb00554.x

Source DB:  PubMed          Journal:  Int J Pept Protein Res        ISSN: 0367-8377


  3 in total

1.  Synthesis of biologically important neutral amylo-β peptide by using improved Fmoc solid-phase peptide synthetic strategy.

Authors:  R Selvam; E Sudha; P R Rajkumar; K P Subashchandran
Journal:  J Chem Biol       Date:  2015-02-26

2.  Difficulties encountered during glycopeptide syntheses.

Authors:  J A Borgia; N B Malkar; H U Abbasi; G B Fields
Journal:  J Biomol Tech       Date:  2001-09

3.  Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells.

Authors:  Anda M Vlad; Stefan Muller; Mare Cudic; Hans Paulsen; Laszlo Otvos; Franz-Georg Hanisch; Olivera J Finn
Journal:  J Exp Med       Date:  2002-12-02       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.